ABBV-243

ABBV-243 is an investigational drug candidate under development by AbbVie, currently in Phase 1 clinical evaluation. The compound is being studied in a randomized, double-blind, placebo-controlled trial to assess its safety, tolerability, pharmacokinetics, and immunogenicity in healthy adult volunteers, including those of Asian descent. The study utilizes a single ascending dose (SAD) design, with the drug being administered via both intravenous infusion and subcutaneous injection. While the specific molecular target and intended clinical indications have not yet been disclosed, the assessment of immunogenicity and the routes of administration suggest the molecule is likely a biologic or monoclonal antibody.

Other names

integrin beta-7 antibody